Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

The role of CT in case ascertainment and management of COVID-19 pneumonia in the UK: insights from high-incidence regions.

Chua F, Armstrong-James D, Desai SR, Barnett J, Kouranos V, Kon OM, José R, Vancheeswaran R, Loebinger MR, Wong J, Cutino-Moguel MT, Morgan C, Ledot S, Lams B, Yip WH, Li L, Lee YC, Draper A, Kho SS, Renzoni E, Ward K, Periselneris J, Grubnic S, Lipman M, Wells AU, Devaraj A.

Lancet Respir Med. 2020 Mar 25. pii: S2213-2600(20)30132-6. doi: 10.1016/S2213-2600(20)30132-6. [Epub ahead of print] No abstract available.

2.

Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent.

Invernizzi R, Barnett J, Rawal B, Nair A, Ghai P, Kingston S, Chua F, Wu Z, Wells AU, Renzoni ER, Nicholson AG, Rice A, Lloyd CM, Byrne AJ, Maher TM, Devaraj A, Molyneaux PL.

Eur Respir J. 2020 Jan 24. pii: 1901519. doi: 10.1183/13993003.01519-2019. [Epub ahead of print]

PMID:
31980496
3.

Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease.

Stock CJW, De Lauretis A, Visca D, Daccord C, Kokosi M, Kouranos V, Margaritopoulos G, George PM, Molyneaux PL, Nihtyanova S, Chua F, Maher TM, Ong V, Abraham DJ, Denton CP, Wells AU, Wain LV, Renzoni EA.

Clin Rheumatol. 2020 Jan 8. doi: 10.1007/s10067-019-04922-6. [Epub ahead of print]

PMID:
31916109
4.

Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.

Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J.

Am J Respir Crit Care Med. 2020 Mar 15;201(6):650-660. doi: 10.1164/rccm.201903-0563CI.

5.

Identifying causation in hypersensitivity pneumonitis: a British perspective.

Barber CM, Burge PS, Feary JR, Parfrey H, Renzoni EA, Spencer LG, Walters GI, Wiggans RE; GB HP Survey Participants.

BMJ Open Respir Res. 2019 Dec 3;6(1):e000469. doi: 10.1136/bmjresp-2019-000469. eCollection 2019.

6.

Cost-effectiveness of ambulatory oxygen in improving quality of life in fibrotic lung disease: preliminary evidence from the AmbOx Trial.

Whitty JA, Rankin J, Visca D, Tsipouri V, Mori L, Spencer L, Adamali H, Maher TM, Hopkinson NS, Birring SS, Farquhar M, Wells AU, Sestini P, Renzoni EA.

Eur Respir J. 2020 Feb 6;55(2). pii: 1901157. doi: 10.1183/13993003.01157-2019. Print 2020 Feb. No abstract available.

PMID:
31699838
7.

Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease.

Alfieri V, Crisafulli E, Visca D, Chong WH, Stock C, Mori L, de Lauretis A, Tsipouri V, Chua F, Kouranos V, Kokosi M, Hogben C, Molyneaux PL, George PM, Maher TM, Chetta AA, Sestini P, Wells AU, Renzoni EA.

Eur Respir J. 2020 Feb 20;55(2). pii: 1901681. doi: 10.1183/13993003.01681-2019. Print 2020 Feb. No abstract available.

PMID:
31699833
8.

Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes.

Kampstra NA, van der Nat PB, Dijksman LM, van Beek FT, Culver DA, Baughman RP, Renzoni EA, Wuyts W, Kouranos V, Zanen P, Wijsenbeek MS, Eijkemans MJC, Biesma DH, van der Wees PJ, Grutters JC.

ERJ Open Res. 2019 Oct 30;5(4). pii: 00094-2019. doi: 10.1183/23120541.00094-2019. eCollection 2019 Oct.

9.

Diffuse alveolar haemorrhage associated with subsequent development of ANCA positivity and emphysema in three young adults.

Stainer A, Rice A, Devaraj A, Barnett JL, Donovan J, Kokosi M, Nicholson AG, Cairns T, Wells AU, Renzoni EA.

BMC Pulm Med. 2019 Oct 24;19(1):185. doi: 10.1186/s12890-019-0947-y.

10.

Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns.

Khor YH, Renzoni EA, Visca D, McDonald CF, Goh NSL.

ERJ Open Res. 2019 Sep 16;5(3). pii: 00118-2019. doi: 10.1183/23120541.00118-2019. eCollection 2019 Jul. Review.

11.

Pleuroparenchymal Fibroelastosis. A Review of Clinical, Radiological, and Pathological Characteristics.

Chua F, Desai SR, Nicholson AG, Devaraj A, Renzoni E, Rice A, Wells AU.

Ann Am Thorac Soc. 2019 Nov;16(11):1351-1359. doi: 10.1513/AnnalsATS.201902-181CME.

12.

Right Ventricular to Left Ventricular Ratio at CT Pulmonary Angiogram Predicts Mortality in Interstitial Lung Disease.

Bax S, Jacob J, Ahmed R, Bredy C, Dimopoulos K, Kempny A, Kokosi M, Kier G, Renzoni E, Molyneaux PL, Chua F, Kouranos V, George P, McCabe C, Wilde M, Devaraj A, Wells A, Wort SJ, Price LC.

Chest. 2020 Jan;157(1):89-98. doi: 10.1016/j.chest.2019.06.033. Epub 2019 Jul 24.

PMID:
31351047
13.

Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis.

Jacob J, Bartholmai BJ, van Moorsel CHM, Rajagopalan S, Devaraj A, van Es HW, Moua T, van Beek FT, Clay R, Veltkamp M, Kokosi M, de Lauretis A, Judge EP, Jacob TM, Peikert T, Karwoski R, Maldonado F, Renzoni E, Maher TM, Altmann A, Wells AU.

Eur Respir J. 2019 Sep 30;54(3). pii: 1802341. doi: 10.1183/13993003.02341-2018. Print 2019 Sep. No abstract available.

14.

Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview.

Mackintosh JA, Stainer A, Barnett JL, Renzoni EA.

Semin Respir Crit Care Med. 2019 Apr;40(2):208-226. doi: 10.1055/s-0039-1683431. Epub 2019 May 28.

PMID:
31137061
15.

Multidisciplinary Evaluation in Patients with Lung Disease Associated with Connective Tissue Disease.

Wells A, Devaraj A, Renzoni EA, Denton CP.

Semin Respir Crit Care Med. 2019 Apr;40(2):184-193. doi: 10.1055/s-0039-1684020. Epub 2019 May 28.

PMID:
31137059
16.

Bromodomain and Extraterminal (BET) Protein Inhibition Restores Redox Balance and Inhibits Myofibroblast Activation.

Stock CJW, Michaeloudes C, Leoni P, Durham AL, Mumby S, Wells AU, Chung KF, Adcock IM, Renzoni EA, Lindahl GE.

Biomed Res Int. 2019 Apr 18;2019:1484736. doi: 10.1155/2019/1484736. eCollection 2019.

17.

Clinical trial design for acute exacerbations in idiopathic pulmonary fibrosis: A thorny path.

Renzoni EA, Wells AU.

Respirology. 2019 Jul;24(7):620-621. doi: 10.1111/resp.13584. Epub 2019 May 15. No abstract available.

18.

Comprehensive Supportive Care for Patients with Fibrosing Interstitial Lung Disease.

Wijsenbeek MS, Holland AE, Swigris JJ, Renzoni EA.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):152-159. doi: 10.1164/rccm.201903-0614PP. Review. No abstract available.

PMID:
31051080
19.

First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative.

Kampstra NA, Grutters JC, van Beek FT, Culver DA, Baughman RP, Renzoni EA, Wuyts W, Kouranos V, Wijsenbeek MS, Biesma DH, van der Wees PJ, van der Nat PB.

BMJ Open Respir Res. 2019 Feb 18;6(1):e000394. doi: 10.1136/bmjresp-2018-000394. eCollection 2019.

20.

The King's Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference.

Sinha A, Patel AS, Siegert RJ, Bajwah S, Maher TM, Renzoni EA, Wells AU, Higginson IJ, Birring SS.

BMJ Open Respir Res. 2019 Feb 18;6(1):e000363. doi: 10.1136/bmjresp-2018-000363. eCollection 2019.

21.

In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia is associated with disease progression and mortality.

Mackintosh JA, Desai SR, Adamali H, Patel K, Chua F, Devaraj A, Kouranos V, Kokosi M, Margaritopoulos G, Renzoni EA, Wells AU, Molyneaux PL, Kumar S, Maher TM, George PM.

Eur Respir J. 2019 May 23;53(5). pii: 1802412. doi: 10.1183/13993003.02412-2018. Print 2019 May. No abstract available.

PMID:
30923184
22.

Research highlights from the 2018 ERS International Congress: interstitial lung diseases.

Alfaro TM, Moor CC, Alfieri V, Jeny F, Kreuter M, Wijsenbeek MS, Renzoni EA, Bargagli E, Nunes H, Spagnolo P, Bonella F, Molina-Molina M, Antoniou K, Poletti V.

ERJ Open Res. 2019 Feb 18;5(1). pii: 00215-2018. doi: 10.1183/23120541.00215-2018. eCollection 2019 Feb. Review.

23.

Pulmonary fibrosis: Genetic analysis of telomere-related genes, telomere length measurement-or both?

Kannengiesser C, Borie R, Renzoni EA.

Respirology. 2019 Feb;24(2):97-98. doi: 10.1111/resp.13456. Epub 2018 Dec 17. No abstract available.

24.

Predicting outcomes in rheumatoid arthritis related interstitial lung disease.

Jacob J, Hirani N, van Moorsel CHM, Rajagopalan S, Murchison JT, van Es HW, Bartholmai BJ, van Beek FT, Struik MHL, Stewart GA, Kokosi M, Egashira R, Brun AL, Cross G, Barnett J, Devaraj A, Margaritopoulos G, Karwoski R, Renzoni E, Maher TM, Wells AU.

Eur Respir J. 2019 Jan 3;53(1). pii: 1800869. doi: 10.1183/13993003.00869-2018. Print 2019 Jan.

25.

The potential impact of azithromycin in idiopathic pulmonary fibrosis.

Macaluso C, Maritano Furcada J, Alzaher O, Chaube R, Chua F, Wells AU, Maher TM, George PM, Renzoni EA, Molyneaux PL.

Eur Respir J. 2019 Feb 14;53(2). pii: 1800628. doi: 10.1183/13993003.00628-2018. Print 2019 Feb. No abstract available.

26.

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice.

Fletcher SV, Jones MG, Renzoni EA, Parfrey H, Hoyles RK, Spinks K, Kokosi M, Kwok A, Warburton C, Titmuss V, Thillai M, Simler N, Maher TM, Brereton CJ, Chua F, Wells AU, Richeldi L, Spencer LG.

ERJ Open Res. 2018 Oct 19;4(4). pii: 00049-2018. doi: 10.1183/23120541.00049-2018. eCollection 2018 Oct.

27.

Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial.

Visca D, Mori L, Tsipouri V, Fleming S, Firouzi A, Bonini M, Pavitt MJ, Alfieri V, Canu S, Bonifazi M, Boccabella C, De Lauretis A, Stock CJW, Saunders P, Montgomery A, Hogben C, Stockford A, Pittet M, Brown J, Chua F, George PM, Molyneaux PL, Margaritopoulos GA, Kokosi M, Kouranos V, Russell AM, Birring SS, Chetta A, Maher TM, Cullinan P, Hopkinson NS, Banya W, Whitty JA, Adamali H, Spencer LG, Farquhar M, Sestini P, Wells AU, Renzoni EA.

Lancet Respir Med. 2018 Oct;6(10):759-770. doi: 10.1016/S2213-2600(18)30289-3. Epub 2018 Aug 28.

28.

New treatment paradigms for connective tissue disease-associated interstitial lung disease.

Kouranos V, Miranda G, Corte TJ, Renzoni EA.

Curr Opin Pulm Med. 2018 Sep;24(5):453-460. doi: 10.1097/MCP.0000000000000508. Review.

PMID:
30020142
29.

Functional associations of pleuroparenchymal fibroelastosis and emphysema with hypersensitivity pneumonitis.

Jacob J, Odink A, Brun AL, Macaluso C, de Lauretis A, Kokosi M, Devaraj A, Desai S, Renzoni E, Wells AU.

Respir Med. 2018 May;138:95-101. doi: 10.1016/j.rmed.2018.03.031. Epub 2018 Mar 30.

30.

Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis.

Jacob J, Bartholmai BJ, Rajagopalan S, van Moorsel CHM, van Es HW, van Beek FT, Struik MHL, Kokosi M, Egashira R, Brun AL, Nair A, Walsh SLF, Cross G, Barnett J, de Lauretis A, Judge EP, Desai S, Karwoski R, Ourselin S, Renzoni E, Maher TM, Altmann A, Wells AU.

Am J Respir Crit Care Med. 2018 Sep 15;198(6):767-776. doi: 10.1164/rccm.201711-2174OC.

31.

Pulmonary lymphatic vessel morphology: a review.

Weber E, Sozio F, Borghini A, Sestini P, Renzoni E.

Ann Anat. 2018 Jul;218:110-117. doi: 10.1016/j.aanat.2018.02.011. Epub 2018 Apr 19. Review.

PMID:
29679722
32.

Genetic predictors of systemic sclerosis-associated interstitial lung disease: a review of recent literature.

Stock CJW, Renzoni EA.

Eur J Hum Genet. 2018 Jun;26(6):765-777. doi: 10.1038/s41431-018-0104-8. Epub 2018 Feb 23. Review.

33.

Year in review 2017: Interstitial lung disease, pulmonary vascular disease and sleep.

Piper AJ, Wort SJ, Renzoni EA, Kouranos V.

Respirology. 2018 Apr;23(4):421-433. doi: 10.1111/resp.13273. Epub 2018 Feb 22. Review. No abstract available.

34.

Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease.

Jacob J, Song JW, Yoon HY, Cross G, Barnett J, Woo WL, Adams F, Kokosi M, Devaraj A, Renzoni E, Maher TM, Kim DS, Wells AU.

EBioMedicine. 2018 Feb;28:303-310. doi: 10.1016/j.ebiom.2018.01.038. Epub 2018 Jan 31.

35.

Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization.

Keir GJ, Wort SJ, Kokosi M, George PM, Walsh SLF, Jacob J, Price L, Bax S, Renzoni EA, Maher TM, MacDonald P, Hansell DM, Wells AU.

Respirology. 2018 Jul;23(7):687-694. doi: 10.1111/resp.13250. Epub 2018 Jan 12.

36.

Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema.

Jacob J, Bartholmai BJ, Rajagopalan S, Karwoski R, Nair A, Walsh SLF, Barnett J, Cross G, Judge EP, Kokosi M, Renzoni E, Maher TM, Wells AU.

Respirology. 2018 Jun;23(6):593-599. doi: 10.1111/resp.13231. Epub 2017 Dec 13.

37.

An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study.

Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, Flynn A, Molyneaux PL, Braybrooke R, Divyateja H, Parfrey H, Rassl D, Russell AM, Saini G, Renzoni EA, Duggan AM, Hubbard R, Wells AU, Lukey PT, Marshall RP, Jenkins RG.

Lancet Respir Med. 2017 Dec;5(12):946-955. doi: 10.1016/S2213-2600(17)30430-7. Epub 2017 Nov 14.

38.

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis.

van Manen MJG, Birring SS, Vancheri C, Vindigni V, Renzoni E, Russell AM, Wapenaar M, Cottin V, Wijsenbeek MS.

Eur Respir J. 2017 Oct 19;50(4). pii: 1701157. doi: 10.1183/13993003.01157-2017. Print 2017 Oct. No abstract available.

39.

Pleuroparenchymal Fibroelastosis: A Review of Histopathologic Features and the Relationship Between Histologic Parameters and Survival.

Khiroya R, Macaluso C, Montero MA, Wells AU, Chua F, Kokosi M, Maher TM, Devaraj A, Rice A, Renzoni EA, Nicholson AG.

Am J Surg Pathol. 2017 Dec;41(12):1683-1689. doi: 10.1097/PAS.0000000000000928.

40.

Pulmonary Sarcoidosis.

Bonifazi M, Gasparini S, Alfieri V, Renzoni EA.

Semin Respir Crit Care Med. 2017 Aug;38(4):437-449. doi: 10.1055/s-0037-1603766. Epub 2017 Jul 27. Review. No abstract available.

PMID:
28750459
41.

Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis.

Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Maher TM, Nair A, Karwoski R, Renzoni E, Walsh SLF, Hansell DM, Wells AU.

Eur Respir J. 2017 Jul 5;50(1). pii: 1700379. doi: 10.1183/13993003.00379-2017. Print 2017 Jul.

42.

Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.

Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, Babalis D, Renzoni EA, Denton CP, Wells AU, Maher TM.

Trials. 2017 Jun 15;18(1):275. doi: 10.1186/s13063-017-2016-2.

43.

Fibrotic Hypersensitivity Pneumonitis: Key Issues in Diagnosis and Management.

Kouranos V, Jacob J, Nicholson A, Renzoni E.

J Clin Med. 2017 Jun 15;6(6). pii: E62. doi: 10.3390/jcm6060062. Review.

44.

Use of Patterned Collagen Coated Slides to Study Normal and Scleroderma Lung Fibroblast Migration.

Ahmed Abdi B, Lopez H, Karrar S, Renzoni E, Wells A, Tam A, Etomi O, Hsuan JJ, Martin GR, Shiwen X, Denton CP, Abraham D, Stratton R.

Sci Rep. 2017 Jun 1;7(1):2628. doi: 10.1038/s41598-017-02621-3.

45.

Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial.

Visca D, Tsipouri V, Mori L, Firouzi A, Fleming S, Farquhar M, Leung E, Maher TM, Cullinan P, Hopkinson N, Wells AU, Banya W, Whitty JA, Adamali H, Spencer LG, Sestini P, Renzoni EA.

Trials. 2017 Apr 28;18(1):201. doi: 10.1186/s13063-017-1912-9.

46.

Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.

Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, Nicholson AG, Wells AU.

Arthritis Rheumatol. 2017 Aug;69(8):1670-1678. doi: 10.1002/art.40130. Epub 2017 Jul 18.

47.

Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.

Kreuter M, Spagnolo P, Wuyts W, Renzoni E, Koschel D, Bonella F, Maher TM, Kolb M, Weycker D, Kirchgässler KU, Costabel U.

Respiration. 2017;93(6):415-423. doi: 10.1159/000468546. Epub 2017 Apr 12.

48.

British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders.

Hurst JR, Verma N, Lowe D, Baxendale HE, Jolles S, Kelleher P, Longhurst HJ, Patel SY, Renzoni EA, Sander CR, Avery GR, Babar JL, Buckland MS, Burns S, Egner W, Gompels MM, Gordins P, Haddock JA, Hart SP, Hayman GR, Herriot R, Hoyles RK, Huissoon AP, Jacob J, Nicholson AG, Rassl DM, Sargur RB, Savic S, Seneviratne SL, Sheaff M, Vaitla PM, Walters GI, Whitehouse JL, Wright PA, Condliffe AM.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):938-945. doi: 10.1016/j.jaip.2017.01.021. Epub 2017 Mar 25. Review.

49.

Idiopathic Pleuroparenchymal Fibroelastosis.

Bonifazi M, Montero MA, Renzoni EA.

Curr Pulmonol Rep. 2017;6(1):9-15. doi: 10.1007/s13665-017-0160-5. Epub 2017 Jan 27. Review.

50.

Patient-reported outcome measures in idiopathic pulmonary fibrosis: Where do we stand?

Canu S, Alfieri V, Renzoni E.

Respirology. 2017 May;22(4):628-629. doi: 10.1111/resp.13030. Epub 2017 Mar 22. No abstract available.

Supplemental Content

Loading ...
Support Center